Business Description
ZyVersa Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98987D3008
Total Employee Number:
6Description
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | -19.04 | |||||
Debt-to-Equity | -0.09 | |||||
Debt-to-EBITDA | -0.05 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 72.2 | |||||
3-Year EPS without NRI Growth Rate | 84.9 | |||||
3-Year FCF Growth Rate | 65.9 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.71 | |||||
9-Day RSI | 42.79 | |||||
14-Day RSI | 43.8 | |||||
3-1 Month Momentum % | 2.4 | |||||
6-1 Month Momentum % | 53.29 | |||||
12-1 Month Momentum % | -69.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.05 | |||||
Quick Ratio | 0.05 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -577.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -286.37 | |||||
ROIC % | -73.68 | |||||
3-Year ROIIC % | -5.64 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -0.09 | |||||
EV-to-EBITDA | -0.09 | |||||
EV-to-FCF | -0.54 | |||||
Earnings Yield (Greenblatt) % | -1111.11 | |||||
FCF Yield % | -306.36 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZVSA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ZyVersa Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -2.79 | ||
| Beta | 0.9885 | ||
| 3-Year Sharpe Ratio | -1.28 | ||
| 3-Year Sortino Ratio | -1.53 | ||
| Volatility % | 117.63 | ||
| 14-Day RSI | 43.8 | ||
| 14-Day ATR ($) | 0.024453 | ||
| 20-Day SMA ($) | 0.176603 | ||
| 12-1 Month Momentum % | -69.75 | ||
| 52-Week Range ($) | 0.11 - 1.67 | ||
| Shares Outstanding (Mil) | 8.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ZyVersa Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ZyVersa Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 0.1:1 Stock Split | 2024-04-26 | 6.08 (+5.12%) | ||
| 0.0285714:1 Stock Split | 2023-12-05 | 21.66 (+3.34%) |
Show
Entries
ZyVersa Therapeutics Inc Frequently Asked Questions
What is ZyVersa Therapeutics Inc(ZVSA)'s stock price today?
The current price of ZVSA is $0.17. The 52 week high of ZVSA is $1.67 and 52 week low is $0.11.
When is next earnings date of ZyVersa Therapeutics Inc(ZVSA)?
The next earnings date of ZyVersa Therapeutics Inc(ZVSA) is .
Does ZyVersa Therapeutics Inc(ZVSA) pay dividends? If so, how much?
ZyVersa Therapeutics Inc(ZVSA) does not pay dividend.
Guru Commentaries on OTCPK:ZVSA
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| ZyVersa Therapeutics Adds Two Esteemed Leaders in Nephrology to Its Renal Scientific Advisory Board to Support Clinical Advancement of Lead Renal Drug Candidate, VAR 200 | 2023-01-03 |
Articles on ZyVersa Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers